CLL14 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

62 results for “CLL14”

Trials

View all 28 →

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 participants · First posted Sep 17, 2014

VIDAS Nephroclear (NCL) CCL14 - Sample Stability

40 participants · First posted Mar 9, 2022

Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)

20 participants · First posted May 13, 2021

Drugs

View all 30 →

VOR33-CLL1/VCAR33-CLL1

CLL1-TDB

CLL1 ThisCART

News

AbbVie and Roche Seek FDA Approval for Venclexta-Gazyva Combination in First-line CLL Treatment

Measurable Residual Disease as Surrogate Endpoint in CLL Trials: Methodological Concerns Raised Over Meta-Analysis Findings

FDA Approves Roche-AbbVie's Venclexta Plus Gazyva as First-Line Chemotherapy-Free Treatment for CLL

Page 1 of 7